NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
Provided By PR Newswire
Last update: Dec 18, 2024
CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and third quarter financial results.
Read more at prnewswire.com
